98%
921
2 minutes
20
Objective: To establish a prognostic model for endometrial cancer (EC) that individualizes a risk and management plan per patient and disease characteristics.
Methods: A multicenter retrospective study conducted in nine European gynecologic cancer centers. Women with confirmed EC between January 2008 to December 2015 were included. Demographics, disease characteristics, management, and follow-up information were collected. Cancer-specific survival (CSS) and disease-free survival (DFS) at 3 and 5 years comprise the primary outcomes of the study. Machine learning algorithms were applied to patient and disease characteristics. Model I: pretreatment model. Calculated probability was added to management variables (model II: treatment model), and the second calculated probability was added to perioperative and postoperative variables (model III).
Results: Of 1150 women, 1144 were eligible for 3-year survival analysis and 860 for 5-year survival analysis. Model I, II, and III accuracies of prediction of 5-year CSS were 84.88%/85.47% (in train and test sets), 85.47%/84.88%, and 87.35%/86.05%, respectively. Model I predicted 3-year CSS at an accuracy of 91.34%/87.02%. Accuracies of models I, II, and III in predicting 5-year DFS were 74.63%/76.72%, 77.03%/76.72%, and 80.61%/77.78%, respectively.
Conclusion: The Endometrial Cancer Individualized Scoring System (ECISS) is a novel machine learning tool assessing patient-specific survival probability with high accuracy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ijgo.14639 | DOI Listing |
Bioact Mater
December 2025
Division of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
The endometrium is a vital mucosal tissue which undergoes cyclical regeneration, differentiation, and remodeling upon hormonal, cellular, and molecular signaling networks. Dysregulation of these processes can trigger a range of pathological conditions including chronic inflammatory disorders, hyperplastic lesions, malignancies, and infertility, necessitating the need for effective therapeutic interventions. Furthermore, we are still dependent on conventional treatment modalities which are often constrained by inefficient drug biodistribution, systemic toxicity, and emergence of therapeutic resistance.
View Article and Find Full Text PDFHealth Equity
August 2025
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
Objectives: Black patients have the highest mortality rate from endometrial cancer (EC), and yet remain underrepresented in EC research. Thus, currently published symptom patterns may not be comprehensive for this population. The purpose of this study is to analyze symptomatology among Black patients with EC in the Guidelines for Ultrasound in the Detection of Early Endometrial Cancer study and to compare with those undergoing benign hysterectomy.
View Article and Find Full Text PDFGynecol Oncol Rep
October 2025
University of California, Irvine, Irvine, CA, USA.
Obesity is a well-established risk factor for endometrial cancer, driven by chronic inflammation, insulin resistance, and excess estrogen. As the global obesity epidemic continues to worsen, effective weight management plays a crucial role in reducing both incidence and progression. Recent pharmacotherapy advancements, particularly GLP-1 receptor agonists, show promising weight loss effects by modulating appetite and metabolism.
View Article and Find Full Text PDFProteomics Clin Appl
September 2025
AIBioMed Research Group, Taipei Medical University, Taipei, Taiwan.
Background: Endometrial carcinoma (EC) represents a significant clinical challenge due to its pronounced molecular heterogeneity, directly influencing prognosis and therapeutic responses. Accurate classification of molecular subtypes (CNV-high, CNV-low, MSI-H, POLE) and precise tumor mutational burden (TMB) assessment is crucial for guiding personalized therapeutic interventions. Integrating proteomics data with advanced machine learning (ML) techniques offers a promising strategy for achieving precise, clinically actionable classification and biomarker discovery in EC.
View Article and Find Full Text PDFInt J Gynecol Cancer
August 2025
Radiation Department, A.O. S. Croce e Carle Teaching Hospital, Cuneo CN, Italy.